2024
Identification and validation of urinary CXCL9 as a biomarker for diagnosis of acute interstitial nephritis
Moledina D, Obeid W, Smith R, Rosales I, Sise M, Moeckel G, Kashgarian M, Kuperman M, Campbell K, Lefferts S, Meliambro K, Bitzer M, Perazella M, Luciano R, Pober J, Cantley L, Colvin R, Wilson F, Parikh C. Identification and validation of urinary CXCL9 as a biomarker for diagnosis of acute interstitial nephritis. Journal Of Clinical Investigation 2024, 134: e180583. PMID: 38488004, PMCID: PMC10940080, DOI: 10.1172/jci180583.Peer-Reviewed Original ResearchConceptsDiagnosis of acute interstitial nephritisAcute interstitial nephritisUrinary CXCL9Interstitial nephritis
2023
Identification and validation of urinary CXCL9 as a biomarker for diagnosis of acute interstitial nephritis
Moledina D, Obeid W, Smith R, Rosales I, Sise M, Moeckel G, Kashgarian M, Kuperman M, Campbell K, Lefferts S, Meliambro K, Bitzer M, Perazella M, Luciano R, Pober J, Cantley L, Colvin R, Wilson F, Parikh C. Identification and validation of urinary CXCL9 as a biomarker for diagnosis of acute interstitial nephritis. Journal Of Clinical Investigation 2023, 133: e168950. PMID: 37395276, PMCID: PMC10313360, DOI: 10.1172/jci168950.Peer-Reviewed Original ResearchConceptsUrinary CXCL9External validation cohortValidation cohortControl groupAIN diagnosisDiscovery cohortKidney tissueDiagnostic biomarkersAcute interstitial nephritisCXCL9 mRNA expressionAcute kidney injuryBiopsy-confirmed diagnosisAvailable clinical testsNational InstituteKidney injuryTubulointerstitial nephritisInterstitial nephritisKidney biopsyHistological confirmationHistological diagnosisTreatment optionsLymphocyte chemotaxisCXCL9MRNA expression differencesPatients
2022
Immune checkpoints inhibitors and its link to acute kidney injury and renal prognosis
Kanbay M, Yildiz AB, Siriopol D, Vehbi S, Hasbal NB, Kesgin YE, Celayir M, Selcukbiricik F, Covic A, Perazella MA. Immune checkpoints inhibitors and its link to acute kidney injury and renal prognosis. International Urology And Nephrology 2022, 55: 1025-1032. PMID: 36282399, DOI: 10.1007/s11255-022-03395-y.Peer-Reviewed Original ResearchConceptsAcute kidney injuryImmune checkpoint inhibitorsSolid organ malignanciesCheckpoint inhibitorsKidney injuryOrgan malignanciesNephrotoxic agentsSingle-center retrospective cohort studyType of ICIBaseline serum creatinine levelAcute interstitial nephritisLocation of malignancyRetrospective cohort studySerum creatinine levelsKidney function recoveryRenal replacement therapyUrinary tract obstructionRisk of mortalityICPI treatmentRenal prognosisTract obstructionCohort studyCreatinine levelsFive patientsInterstitial nephritisDrug-Induced Acute Kidney Injury
Perazella MA, Rosner MH. Drug-Induced Acute Kidney Injury. Clinical Journal Of The American Society Of Nephrology 2022, 17: 1220-1233. PMID: 35273009, PMCID: PMC9435983, DOI: 10.2215/cjn.11290821.Peer-Reviewed Original ResearchConceptsKidney injuryTubular injuryDrug-induced acute kidney injuryT cell-mediated immune responsesDrug-related kidney injuryCell-mediated immune responsesAcute interstitial nephritisDirect tubular injuryTreatment of AKIAcute kidney injuryAcute tubular injuryIntensive care unitInduction of inflammationAKI riskIntratubular obstructionTubulointerstitial injuryInterstitial nephritisCare unitInflammation leadInjury resultsCommon causeImmune responseHospital wardsProximal tubulesAKIMortality after acute kidney injury and acute interstitial nephritis in patients prescribed immune checkpoint inhibitor therapy
Baker ML, Yamamoto Y, Perazella MA, Dizman N, Shirali AC, Hafez N, Weinstein J, Simonov M, Testani JM, Kluger HM, Cantley LG, Parikh CR, Wilson FP, Moledina DG. Mortality after acute kidney injury and acute interstitial nephritis in patients prescribed immune checkpoint inhibitor therapy. Journal For ImmunoTherapy Of Cancer 2022, 10: e004421. PMID: 35354588, PMCID: PMC8968986, DOI: 10.1136/jitc-2021-004421.Peer-Reviewed Original ResearchConceptsAcute interstitial nephritisAcute kidney injuryImmune checkpoint inhibitor therapyCheckpoint inhibitor therapyICI therapyKidney injuryInhibitor therapyInterstitial nephritisTime-varying Cox proportional hazards modelsHigher peak serum creatinineSevere acute kidney injuryCancer typesCox proportional hazards modelAssociations of biopsyBaseline laboratory valuesObservational cohort studyPeak serum creatinineFavorable treatment responseProportional hazards modelAKI patientsTherapy initiationCohort studySerum creatinineUnivariable analysisImmune activation
2021
Development and external validation of a diagnostic model for biopsy-proven acute interstitial nephritis using electronic health record data
Moledina DG, Eadon MT, Calderon F, Yamamoto Y, Shaw M, Perazella MA, Simonov M, Luciano R, Schwantes-An TH, Moeckel G, Kashgarian M, Kuperman M, Obeid W, Cantley LG, Parikh CR, Wilson FP. Development and external validation of a diagnostic model for biopsy-proven acute interstitial nephritis using electronic health record data. Nephrology Dialysis Transplantation 2021, 37: 2214-2222. PMID: 34865148, PMCID: PMC9755995, DOI: 10.1093/ndt/gfab346.Peer-Reviewed Original ResearchConceptsAcute interstitial nephritisInterstitial nephritisUrine biomarkersBiopsy-proven acute interstitial nephritisElectronic health record dataExternal validation cohortTypical clinical featuresBlood urea nitrogenTumor necrosis factorCharacteristic curve analysisHealth record dataExternal validationElectronic health recordsAIN diagnosisModest AUCsSerum creatinineCreatinine ratioKidney biopsyClinical featuresValidation cohortNecrosis factorUnrecognized casesInterleukin-9PatientsUrea nitrogen
2020
Urine interleukin-9 and tumor necrosis factor-α for prognosis of human acute interstitial nephritis
Moledina DG, Wilson FP, Kukova L, Obeid W, Luciano R, Kuperman M, Moeckel GW, Kashgarian M, Perazella MA, Cantley LG, Parikh CR. Urine interleukin-9 and tumor necrosis factor-α for prognosis of human acute interstitial nephritis. Nephrology Dialysis Transplantation 2020, 36: 1851-1858. PMID: 33125471, PMCID: PMC8476079, DOI: 10.1093/ndt/gfaa169.Peer-Reviewed Original ResearchConceptsAcute interstitial nephritisTumor necrosis factorCorticosteroid useIL-9Interstitial nephritisNecrosis factorAcute kidney injuryIL-9 levelsGlomerular filtration rateSubset of patientsCohort of participantsImmunosuppressive therapyTubulointerstitial infiltratesKidney injuryMedian eGFRKidney functionUrine biomarkersInterstitial fibrosisFiltration rateHistological featuresClinical trialsInterleukin-9PatientsEGFRComplete data
2019
Diagnosing acute interstitial nephritis: considerations for clinicians
Nussbaum E, Perazella M. Diagnosing acute interstitial nephritis: considerations for clinicians. Clinical Kidney Journal 2019, 12: 808-813. DOI: 10.1093/ckj/sfz080.Peer-Reviewed Original ResearchAcute interstitial nephritisAcute kidney injuryAcute tubular necrosisInterstitial nephritisCommon causeDirect further managementKidney injuryMost patientsTubular necrosisKidney biopsyClinical historyFurther managementCliniciansLaboratory dataNephritisPatientsInjuryDiagnosisSingle testCauseBiopsyNecrosisBiomarkers
2018
Drug-Induced Acute Kidney Injury
Luciano R, Perazella M. Drug-Induced Acute Kidney Injury. 2018, 145-163. DOI: 10.1007/978-1-4939-8628-6_9.Peer-Reviewed Original ResearchDrug-induced acute kidney injuryAcute kidney injuryKidney injuryAcute tubular injury/necrosisAcute interstitial nephritisFocal segmental glomerulosclerosisDrugs/substancesOsmotic nephropathyRisk patientsInterstitial nephritisKidney functionPrescribed medicationsSegmental glomerulosclerosisEarly identificationRenal compartmentsInjuryHarmful drugsTherapeutic agentsAdverse effectsCommon formDrugsMedicationsKidneyCommon problemDiagnostic agentsCancer drugs and the glomerulus
Shah H, Uppal N, Perazella M. Cancer drugs and the glomerulus. Journal Of Onco-Nephrology 2018, 2: 78-91. DOI: 10.1177/2399369318815418.Peer-Reviewed Original ResearchGlomerular lesionsCancer drugsAnti-vascular endothelial growth factor inhibitorsPoor renal outcomeAcute interstitial nephritisAcute kidney injuryAcute tubular necrosisGrowth factor inhibitorsMinimal change diseaseFocal segmental glomerulosclerosisTyrosine kinase inhibitorsNovel cancer drugsRenal outcomesKidney injuryThrombotic microangiopathyNovel immunotherapiesTubular injuryTubular necrosisInterstitial nephritisGlomerular toxicityChange diseaseFactor inhibitorsSegmental glomerulosclerosisGlomerular diseasePodocyte injury
2017
Update on the Renal Effects of Anticancer Agents
Perazella M. Update on the Renal Effects of Anticancer Agents. Journal Of Onco-Nephrology 2017, 1: 170-178. DOI: 10.5301/jo-n.5000026.Peer-Reviewed Original ResearchAnticancer drug nephrotoxicityChronic kidney injuryKidney injuryDrug nephrotoxicityAcute interstitial nephritisAcute kidney injuryAcute tubular injuryNumber of drugsNumber of lesionsAcid-base disturbancesNephrology updateRenal effectsNovel immunotherapiesTubular injuryInterstitial nephritisGlomerular injuryKidney diseaseCancer patientsConventional chemotherapyRenal metabolismSystemic toxicityInjuryNephrotoxicityChemotherapeutic drugsPatients
2015
Drug-Induced Glomerular Disease: Direct Cellular Injury
Markowitz GS, Bomback AS, Perazella MA. Drug-Induced Glomerular Disease: Direct Cellular Injury. Clinical Journal Of The American Society Of Nephrology 2015, 10: 1291-1299. PMID: 25862776, PMCID: PMC4491280, DOI: 10.2215/cjn.00860115.Peer-Reviewed Original ResearchConceptsGlomerular diseaseCell injuryGlomerular lesionsNonsteroidal anti-inflammatory drugsAcute interstitial nephritisDrug-induced etiologyPotential of medicationsRenal function recoveryAcute tubular necrosisEndothelial cell injuryMesangial cell injuryEpithelial cell injuryAnti-inflammatory drugsDirect cellular injuryRapid discontinuationKidney injuryTubular necrosisAntiplatelet agentsInterstitial nephritisTubulointerstitial compartmentFunction recoveryIatrogenic formCellular injuryAntiangiogenesis drugsInjury
2008
Proton pump inhibitors: acute interstitial nephritis and other renal effects
Brewster U, Perazella M. Proton pump inhibitors: acute interstitial nephritis and other renal effects. 2008, 567-577. DOI: 10.1007/978-0-387-84843-3_25.Peer-Reviewed Original ResearchAcute interstitial nephritisProton pump inhibitorsInterstitial nephritisEnd-stage renal diseaseAnti-ulcer therapyChronic interstitial nephritisChronic interstitial diseaseDrug-drug interactionsRenal complicationsRenal effectsRenal diseasePump inhibitorsEfficacy profileInterstitial diseaseNephritisPrescribed classOmeprazoleDisease